ACCESS Newswire
13 May 2019, 21:25 GMT+10
SAN DIEGO, CA / ACCESSWIRE / May 13, 2019 / Calidi Biotherapeutics, Inc. is proud to announce the founding and launch of a scientific and medical advisory board (SMAB). The board, consisting of several leaders in the immuno-oncology field, will provide vital input and guidance for Calidi Biotherapeutics to further develop immunotherapies for cancer treatment. Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company aimed at transforming the way cancer is treated by developing oncolytic virus-based immunotherapies.
The scientific advisory board members include Lisa H. Butterfield, Ph.D., the current Vice President of the Parker Institute for Cancer Immunotherapy Research Center and past President of the Society for Immunotherapy of Cancer; Francesco Marincola, M.D., current Chief Scientific Officer at Refuge Biotech and the past President of the Society for Immunotherapy of Cancer; and Santosh Kesari, M.D., Ph.D., current Director of Pacific Neuroscience Institute Research Center and Chair of the Department of Translational Neurosciences and Neurotherapeutics at John Wayne Cancer Institute at Providence Saint John's Health Center.
Allan J. Camaisa, CEO and Chairman of Calidi Biotherapeutics, said the company is honored to have the support and invaluable advice of the founding board members.
'All three SMAB members are world-renowned experts in tumor immunology and immunotherapy for cancer,' said Allan J. Camaisa. 'Their contributions in the field of immuno-oncology have been widely recognized, and they will be a tremendous resource for Calidi Biotherapeutics as we conduct clinical trials with our patented oncolytic virus-based platform.'
Boris Minev, M.D., President, Medical and Scientific Affairs of Calidi Biotherapeutics said, 'The members of our newly formed scientific and medical advisory board are key authorities in cancer immunotherapy and their contributions to Calidi Biotherapeutics will be invaluable as we move towards our next phase of clinical development and growth.'
For more information, visit https://calidibio.com/
About Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage biotechnology company with proprietary technology that overcomes the challenges to effective delivery of oncolytic viruses. Calidi Biotherapeutics is advancing its cell-based oncolytic virus delivery platform in an Investigational New Drug (IND) application for the treatment of prostate cancer, based on previous guidance the company has received from the Food and Drug Administration (FDA) and Calidi's scientific, clinical and regulatory expert advisors.
For more information, please contact:
(858) 794-9600
Aimee Eucce
[email protected]
SOURCE: Calidi Biotherapeutics, Inc.
Get a daily dose of Boston Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Boston Star.
More InformationWASHINGTON, D.C.: A federal rule designed to make it easier for Americans to cancel subscriptions has been blocked by a U.S. appeals...
BASTROP, Texas: In a surprising turn at Elon Musk's X platform, CEO Linda Yaccarino announced she is stepping down, just months after...
NEW YORK CITY, New York: Former British prime minister Rishi Sunak will return to Goldman Sachs in an advisory role, the Wall Street...
LONDON, U.K.: Physically backed gold exchange-traded funds recorded their most significant semi-annual inflow since the first half...
AMSTERDAM, Netherlands: Some 32 percent of global semiconductor production could face climate change-related copper supply disruptions...
NEW YORK, New York - U.S. stocks rebounded Tuesday with all the major indices gaining ground. Markets in the UK, Europe and Canada...
WASHINGTON, D.C.: Travelers at U.S. airports will no longer need to remove their shoes during security screenings, Department of Homeland...
(Photo credit: David Butler II-Imagn Images) Boston Red Sox starting pitcher Hunter Dobbins exited Friday night's game against the...
(Photo credit: Brad Penner-Imagn Images) New York Yankees left-hander Carlos Rodon was named to the American League All-Star team...
(Photo credit: Geoff Burke-Imagn Images) Boston Legacy FC signed striker Aissata Traore to a three-year contract through the 2028...
(Photo credit: Patrick Breen/The Republic / USA TODAY NETWORK via Imagn Images) Two teams hoping to get back to the .500 mark before...
(Photo credit: Patrick Gorski-Imagn Images) Behind right-hander Quinn Priester, the Milwaukee Brewers will look to continue their...